[go: up one dir, main page]

WO2011084618A3 - Compositions and methods for oral drug delivery - Google Patents

Compositions and methods for oral drug delivery Download PDF

Info

Publication number
WO2011084618A3
WO2011084618A3 PCT/US2010/060809 US2010060809W WO2011084618A3 WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3 US 2010060809 W US2010060809 W US 2010060809W WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drug delivery
oral drug
compositions
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/060809
Other languages
French (fr)
Other versions
WO2011084618A2 (en
Inventor
William W. Lee
Feng Lu
Yin Min
Liuying Shao
Hao SHE
Zhou Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOD Pharmaceuticals Inc
Original Assignee
NOD Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910201248.3A external-priority patent/CN102100912B/en
Priority claimed from CN201010227045.4A external-priority patent/CN102335431B/en
Application filed by NOD Pharmaceuticals Inc filed Critical NOD Pharmaceuticals Inc
Priority to JP2012544835A priority Critical patent/JP2013514976A/en
Priority to CA2784120A priority patent/CA2784120A1/en
Priority to EP10795591A priority patent/EP2512454A2/en
Priority to AU2010339907A priority patent/AU2010339907A1/en
Publication of WO2011084618A2 publication Critical patent/WO2011084618A2/en
Publication of WO2011084618A3 publication Critical patent/WO2011084618A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a pharmaceutical composition for oral drug delivery comprising a solid dosage form containing an effective amount of a therapeutic agent, a permeation enhancer and a pharmaceutically acceptable excipient and a bioadhesive layer containing a bioadhesive polymer, and optionally comprising an impermeable or semi-permeable layer having an opening capable of directing a unidirectional release of the therapeutic agent and the permeation enhancer from the solid dosage form. Methods of making and using the present pharmaceutical composition are also provided.
PCT/US2010/060809 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery Ceased WO2011084618A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012544835A JP2013514976A (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery
CA2784120A CA2784120A1 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery
EP10795591A EP2512454A2 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery
AU2010339907A AU2010339907A1 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28714609P 2009-12-16 2009-12-16
CN200910201248.3 2009-12-16
CN200910201248.3A CN102100912B (en) 2009-12-16 2009-12-16 Administration composition and preparation method and using method thereof
US61/287,146 2009-12-16
CN201010227045.4A CN102335431B (en) 2010-07-14 2010-07-14 A kind of administration composition and preparation and application thereof
CN201010227045.4 2010-07-14
US36591610P 2010-07-20 2010-07-20
US61/365,916 2010-07-20

Publications (2)

Publication Number Publication Date
WO2011084618A2 WO2011084618A2 (en) 2011-07-14
WO2011084618A3 true WO2011084618A3 (en) 2012-01-19

Family

ID=44306059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/060809 Ceased WO2011084618A2 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery

Country Status (5)

Country Link
EP (1) EP2512454A2 (en)
JP (1) JP2013514976A (en)
AU (1) AU2010339907A1 (en)
CA (1) CA2784120A1 (en)
WO (1) WO2011084618A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103557B2 (en) 2014-03-21 2021-08-31 Anygen Co., Ltd. Exenatide analogue and use thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
RU2600440C3 (en) 2010-12-16 2021-12-10 Ново Нордиск А/С SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA2838793C (en) * 2011-07-19 2019-08-06 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (en) 2012-03-22 2019-06-03 Novo Nordisk As Compositions comprising a supply agent and its preparation
HUE064694T2 (en) 2012-03-22 2024-04-28 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
WO2015010927A1 (en) * 2013-07-24 2015-01-29 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
JP7211704B2 (en) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス A tablet containing a GLP-1 agonist and an enteric coating
CN107205949A (en) * 2015-01-29 2017-09-26 诺和诺德股份有限公司 Pharmaceutical composition for oral administration of GLP‑1 comprising a tablet core and an immediate release coating
EP3250225A1 (en) * 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
UA123051C2 (en) * 2015-04-08 2021-02-10 Торрент Фармасьютікалз Лімітед Pharmaceutical formulations
CN113546036A (en) 2015-05-01 2021-10-26 拉尼医疗有限公司 Pharmaceutical composition and method for preparing solid block comprising polypeptide and/or protein
CN104998251A (en) * 2015-07-08 2015-10-28 哈尔滨吉象隆生物技术有限公司 Intestinal absorption promoting liraglutide salt for preparing oral enteric-coated preparations
CN105079794A (en) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 Liraglutide and sulfonylurea compound preparation for oral administration
CN105079793A (en) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 Liraglutide and metformin hydrochloride compound preparation applicable to oral administration
RU2617049C1 (en) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Anticancer drug based on niclosamide
BR112020014624A2 (en) 2018-02-02 2020-12-08 Novo Nordisk A/S SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT)
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4122483B1 (en) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454383A1 (en) * 1990-04-23 1991-10-30 Aicello Chemical Co., Ltd. Large intestinal dissociative polypeptide series oral formulation
EP0460921A2 (en) * 1990-06-04 1991-12-11 Aicello Chemical Company Limited Large intestinal dissociative hard capsules
WO1998032426A1 (en) * 1997-01-29 1998-07-30 Polin Industria Chimica S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO2000041740A2 (en) * 1999-01-11 2000-07-20 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20020044975A1 (en) * 1994-04-22 2002-04-18 Shunsuke Watanabe Colon-specific drug release system
WO2005002549A1 (en) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
EP0200508B1 (en) 1985-04-27 1991-10-02 Nitto Denko Corporation Adhesive oral bandages and oral pharmaceutical preparations
HU198626B (en) 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
US6156731A (en) 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
JP3249147B2 (en) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
CA2070061C (en) 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (en) 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
US5424289A (en) 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
ATE220911T1 (en) 1994-11-17 2002-08-15 Toray Industries TRANSDERMAL ABSORBABLE PREPARATION
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5817624A (en) 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2184316A1 (en) 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU717183B2 (en) 1996-10-30 2000-03-16 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
ATE321882T1 (en) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR ADMINISTRATION OF OLIGONUCLEOTIDES VIA THE ESOPHAUS
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
JPH11246439A (en) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc Transmucosal absorption accelerator
CA2352389C (en) 1998-11-27 2009-01-20 Kanji Takada An oral formulation for gastrointestinal drug delivery
DE60038097T2 (en) 1999-02-22 2009-02-12 Merrion Research I Ltd. SOLID ORAL DOSAGE FORM CONTAINING A RESORPTION AMPLIFIER
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
ATE470433T1 (en) 2004-02-13 2010-06-15 Nod Pharmaceuticals Inc PARTICLES WITH A CORE OF CALCIUM PHOSPHATE NANOPARTICLES, BIOMOLECULE AND BALE ACID, PRODUCTION METHOD AND THERAPEUTIC USE
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090111736A1 (en) 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
EP2285361A2 (en) 2008-05-01 2011-02-23 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454383A1 (en) * 1990-04-23 1991-10-30 Aicello Chemical Co., Ltd. Large intestinal dissociative polypeptide series oral formulation
EP0460921A2 (en) * 1990-06-04 1991-12-11 Aicello Chemical Company Limited Large intestinal dissociative hard capsules
US20020044975A1 (en) * 1994-04-22 2002-04-18 Shunsuke Watanabe Colon-specific drug release system
WO1998032426A1 (en) * 1997-01-29 1998-07-30 Polin Industria Chimica S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO2000041740A2 (en) * 1999-01-11 2000-07-20 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
WO2005002549A1 (en) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103557B2 (en) 2014-03-21 2021-08-31 Anygen Co., Ltd. Exenatide analogue and use thereof

Also Published As

Publication number Publication date
WO2011084618A2 (en) 2011-07-14
EP2512454A2 (en) 2012-10-24
AU2010339907A1 (en) 2012-07-05
JP2013514976A (en) 2013-05-02
CA2784120A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2011084618A3 (en) Compositions and methods for oral drug delivery
WO2009088414A3 (en) Oral pharmaceutical dosage forms
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
AU2007295179A1 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
WO2008120207A3 (en) Compositions for nasal delivery
WO2008038003A3 (en) Pharmaceutical compositions of aripiprazole
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
SI2046298T1 (en) Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition
IL181382A0 (en) Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
WO2012010669A3 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
WO2009140341A3 (en) Atorvastatin compositions
PT2231189T (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
EP2168586A4 (en) Active ingredient of a medicinal agent, a medicinal agent, a pharmaceutical composition and method for treating dementia syndrome patients
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2008060546A3 (en) Oral formulations
ATE479427T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CANDESARTAN-CILEXETIL
WO2008004100A3 (en) Therapeutic compounds
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
WO2010109180A8 (en) Composition for the administration of polymeric drugs
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10795591

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2784120

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010795591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012544835

Country of ref document: JP

Ref document number: 2010339907

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010339907

Country of ref document: AU

Date of ref document: 20101216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1728/KOLNP/2012

Country of ref document: IN